Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rimegepant Sulfate

FDA-approved product (tablet, orally disintegrating, oral), marketed as Nurtec Odt.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rimegepant Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Calcitonin gene-related peptide (cgrp) antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rimegepant Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rimegepant Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders

    NCT05262517 · start 2022-05-05

    Registered record
    Registry ID
    NCT05262517
    Conditions
    Temporomandibular Disorders (TMD)
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-05-05
    Completion
    2023-05-18
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTemporomandibular Disorders (TMD)
    InterventionRimegepant; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

    NCT05207865 · start 2022-03-15

    Registered record
    Registry ID
    NCT05207865
    Conditions
    Migraine; Episodic Migraine; Phonophobia; Photophobia
    Interventions
    Rimegepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-03-15
    Completion
    2024-07-02
    Enrolment
    441

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Episodic Migraine; Phonophobia; Photophobia
    InterventionRimegepant
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

    NCT05217927 · start 2022-03-04

    Registered record
    Registry ID
    NCT05217927
    Conditions
    Migraine
    Interventions
    Rimegepant 75mg daily dosing; Rimegepant 75mg every other day dosing; Placebo comparator dosing
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-03-04
    Completion
    2024-12-11
    Enrolment
    1,415

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant 75mg daily dosing; Rimegepant 75mg every other day dosing; Placebo comparator dosing
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

    NCT05156398 · start 2022-02-28

    Registered record
    Registry ID
    NCT05156398
    Conditions
    Migraine
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-02-28
    Completion
    2032-11-27
    Enrolment
    640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

    NCT05248997 · start 2022-02-17

    Registered record
    Registry ID
    NCT05248997
    Conditions
    Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
    Interventions
    rimegepant 75 mg ODT; Matching placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-02-17
    Completion
    2024-04-02
    Enrolment
    261

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis (CRS) With and Without Nasal Polyps
    Interventionrimegepant 75 mg ODT; Matching placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

    NCT05198245 · start 2021-12-15

    Registered record
    Registry ID
    NCT05198245
    Conditions
    Migraine
    Interventions
    Rimegepant; Various; No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2021-12-15
    Completion
    2028-04-30
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant; Various; No intervention
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

    NCT05127486 · start 2021-12-06

    Registered record
    Registry ID
    NCT05127486
    Conditions
    Migraine; Episodic Migraine
    Interventions
    Galcanezumab; Rimegepant; Placebo; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-12-06
    Completion
    2023-05-23
    Enrolment
    580

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Episodic Migraine
    InterventionGalcanezumab; Rimegepant; Placebo; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

    NCT05046613 · start 2021-09-23

    Registered record
    Registry ID
    NCT05046613
    Conditions
    Migraine
    Interventions
    Rimegepant; Not taking Rimegepant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-09-23
    Completion
    2034-04-30
    Enrolment
    780

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant; Not taking Rimegepant
    PhaseNot recorded
    Registry statusRecruiting

  • An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache

    NCT04860713 · start 2021-04-22

    Registered record
    Registry ID
    NCT04860713
    Conditions
    Pain
    Interventions
    aspirin and ketamine; Nurtec (Rimegepant)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-22
    Completion
    2022-11-17
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    Interventionaspirin and ketamine; Nurtec (Rimegepant)
    PhasePhase 4
    Registry statusCompleted

  • Rimegepant in Moderate Plaque-type Psoriasis

    NCT04629950 · start 2021-01-19

    Registered record
    Registry ID
    NCT04629950
    Conditions
    Psoriasis
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-01-19
    Completion
    2024-11-18
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionRimegepant; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    NCT04649242 · start 2021-01-15

    Registered record
    Registry ID
    NCT04649242
    Conditions
    Pediatric Migraine
    Interventions
    Rimegepant/BHV3000; Matching placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-01-15
    Completion
    2029-01-09
    Enrolment
    2,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Migraine
    InterventionRimegepant/BHV3000; Matching placebo
    PhasePhase 3
    Registry statusRecruiting

  • Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine

    NCT04574362 · start 2020-10-22

    Registered record
    Registry ID
    NCT04574362
    Conditions
    Acute Migraine
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-10-22
    Completion
    2021-12-16
    Enrolment
    1,648

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Migraine
    InterventionRimegepant; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Trial for Treatment Refractory Trigeminal Neuralgia

    NCT03941834 · start 2019-06-25

    Registered record
    Registry ID
    NCT03941834
    Conditions
    Trigeminal Neuralgia
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-06-25
    Completion
    2023-05-11
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrigeminal Neuralgia
    InterventionRimegepant; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

    NCT03732638 · start 2018-11-14

    Registered record
    Registry ID
    NCT03732638
    Conditions
    Migraine
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-11-14
    Completion
    2021-02-02
    Enrolment
    1,590

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Trial in Adult Subjects With Acute Migraines

    NCT03461757 · start 2018-02-27

    Registered record
    Registry ID
    NCT03461757
    Conditions
    Migraine, With or Without Aura
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-02-27
    Completion
    2018-10-15
    Enrolment
    1,811

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine, With or Without Aura
    InterventionRimegepant; Placebo
    PhasePhase 3
    Registry statusCompleted